StockWatch
·
Biotechnology: Laboratory Analytical Instruments
Quarterly ResultNov 10, 2026, 04:17 PM

Revvity Q3 Revenue $728.9M; Net Income $62.3M; Acquires ACD/Labs

AI Summary

Revvity, Inc. reported its third-quarter financial results, with total revenue increasing to $728.9 million and net income rising to $62.3 million ($0.56 per diluted share). For the nine-month period, revenue reached $2.17 billion and net income was $154.8 million ($1.38 per diluted share). The company also announced strategic acquisitions, including Advanced Chemistry Development Inc. (ACD/Labs) and an agreement to acquire Human Cell Design (HCD), alongside plans to divest its Immunodiagnostics business in China.

Key Highlights

  • Revvity, Inc. reported total revenue of $728.9 million for the three months ended October 4, 2026, an increase from $698.9 million in the prior year period.
  • Net income for the three months ended October 4, 2026, was $62.3 million, or $0.56 per diluted share, compared to $46.7 million, or $0.40 per diluted share, in the prior year period.
  • For the nine months ended October 4, 2026, total revenue was $2.17 billion, up from $2.08 billion in the prior year period.
  • Net income for the nine months ended October 4, 2026, was $154.8 million, or $1.38 per diluted share, compared to $142.8 million, or $1.21 per diluted share, in the prior year period.
  • Operating income from continuing operations increased to $95.1 million for the three months ended October 4, 2026, from $81.9 million in the prior year period.
  • The company completed the acquisition of Advanced Chemistry Development Inc. (ACD/Labs) for $72.0 million in cash in Q1 2026.
  • Revvity entered into a definitive agreement to acquire Human Cell Design (HCD) for approximately $52.3 million in cash, expected to close in Q4 2026.
  • The company entered into a definitive agreement to divest its Immunodiagnostics business in China, expected to close by the end of fiscal year 2027.